CPHI 株価分析 — China Pharma Holdings Inc (Healthcare >> Drug Manufacturers - Specialty & Generic)
CPHI に関するよくある質問
CPHIのROE(自己資本利益率)は?
China Pharma Holdings IncのROEは-9.53%です。
CPHIの配当利回りは?
China Pharma Holdings Incの配当利回りは0.00%です。
CPHIの品質スコア(Quality Score)は?
当社のAIはCPHIの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CPHIは今が買い時ですか?
当社AIのタイミングスコアは100点中71点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CPHIはどのセクターに属しますか?
China Pharma Holdings IncはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます(NYSE MKT市場)
CPHI AI Analysis Summary
Our AI summary for CPHI: China Pharma Holdings Inc (NYSE MKT), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at ROE of -9.53%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 71/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.26
Price
0.08
(6.78%)
Day Change
|
|
|---|
CPHI, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
38% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.26 |
| PBV / Sector |
1.24 / 10.19
GOOD
|
| Earning Per Share | -0.10 |
| PE / Sector |
N/A / 31.74
|
| PEG or PE/Growth / Sector |
N/A / -0.02
|
| Average 1M Daily Value |
41.00 M
GREAT
|
| Average 1W Daily Value |
1.08 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:49 |
| Symbol | CPHI |
| Name | CHINA PHARMA HOLDINGS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NYSE MKT |
| Listed Shares | 40.52 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 46.20 / 10,556.24 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: No. 17, Jinpan Road, Haikou, China, 570216
Phone: 86 89 8668 11730
Website: https://www.chinapharmaholdings.com
Employees: 215
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google